Goldman Sachs assigns a "neutral" rating to Fortrea (NASDAQ:FTRE) with a $28.00 price target.
Goldman Sachs initiates coverage on Fortrea (NASDAQ:FTRE) with a "neutral" rating and a $28.00 price target, implying a potential upside of 5.62%. The consensus rating for FTRE from 12 analysts covering the stock is "Moderate Buy" with an average 1-year target price of $32.30. Fortrea has a consensus price target of $32.30, suggesting a potential upside of 21.84% and a higher possible upside compared to its competitors in the "Medical laboratories" industry.
June 08, 2024
6 Articles